Enhanced rational protein engineering to reduce viscosity in high-concentration IgG1 antibody solutions

Subcutaneous (SC) delivery of therapeutic antibodies can offer multiple benefits to patients and healthcare providers, including convenience, time savings, and cost reduction. To improve the SC injection experience, drug developers may seek a low injection volume (1-2 mL), which for some antibody drugs necessitates a high concentration solution (≥100 mg/mL) to meet dosage requirements. Several molecular-level challenges hinder the development of high concentration antibody drug products, including high viscosity caused by reversible self-association (RSA). Here, we take an enhanced rational design approach to reduce RSA via protein engineering. Using hydrogen-deuterium exchange mass spectrometry (HDX-MS), we identified potential self-interaction hotspots on the surface of an in-house IgG1 which has known viscosity issues at high concentration. Then, using <i>in silico</i> antibody modeling, we identified sites near the complementary-determining regions for targeting by rational mutagenesis, which included predicted patches of charge or hydrophobicity within or near peptides highlighted by HDX-MS. Screening of nearly 70 variants using dynamic light scattering (DLS) and affinity capture self-interaction nanospectroscopy (AC-SINS) at low concentration showed decreased self-interaction in many variants. Viscosity at 150 mg/mL was reduced by 70% for 13 variants, while two of these variants designed to reduce surface hydrophobicity were found to retain antigen binding compared to the parent antibody. DLS and AC-SINS measurements of self-association were found to correlate with viscosity at high concentration, reinforcing their utility as effective low-concentration screening tools for viscosity. This work demonstrates an enhanced rational mutagenesis strategy informed by the combination of HDX-MS for self-association and <i>in silico</i> predictions of surface properties. The resulting variants are a vast improvement on the parent antibody's viscosity issues and offer insight into the mechanism of self-association.

Authors

Institutions

Publication Details

Journal
mAbs
Published
2025-08-08
DOI
https://doi.org/10.1080/19420862.2025.2543771
Citations
4
Primary Topic
Protein purification and stability
Type
article
Field-Weighted Citation Impact
3.22

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Enhanced rational protein engineering to reduce viscosity in high-concentration IgG1 antibody solutions

Joseph L. Caldwell, Gilad Kaplan, Reza Esfandiary, E. R. Houston et al.
4 citations
mAbs
Protein purification and stability
3.22
article

Enhanced rational protein engineering to reduce viscosity in high-concentration IgG1 antibody solutions

Joseph L. Caldwell, Gilad Kaplan, Reza Esfandiary, E. R. Houston, Austin Gallegos, Tyler J. Lefevre, Qun Du
article en
4 citations

Abstract

Subcutaneous (SC) delivery of therapeutic antibodies can offer multiple benefits to patients and healthcare providers, including convenience, time savings, and cost reduction. To improve the SC injection experience, drug developers may seek a low injection volume (1-2 mL), which for some antibody drugs necessitates a high concentration solution (≥100 mg/mL) to meet dosage requirements. Several molecular-level challenges hinder the development of high concentration antibody drug products, including high viscosity caused by reversible self-association (RSA). Here, we take an enhanced rational design approach to reduce RSA via protein engineering. Using hydrogen-deuterium exchange mass spectrometry (HDX-MS), we identified potential self-interaction hotspots on the surface of an in-house IgG1 which has known viscosity issues at high concentration. Then, using <i>in silico</i> antibody modeling, we identified sites near the complementary-determining regions for targeting by rational mutagenesis, which included predicted patches of charge or hydrophobicity within or near peptides highlighted by HDX-MS. Screening of nearly 70 variants using dynamic light scattering (DLS) and affinity capture self-interaction nanospectroscopy (AC-SINS) at low concentration showed decreased self-interaction in many variants. Viscosity at 150 mg/mL was reduced by 70% for 13 variants, while two of these variants designed to reduce surface hydrophobicity were found to retain antigen binding compared to the parent antibody. DLS and AC-SINS measurements of self-association were found to correlate with viscosity at high concentration, reinforcing their utility as effective low-concentration screening tools for viscosity. This work demonstrates an enhanced rational mutagenesis strategy informed by the combination of HDX-MS for self-association and <i>in silico</i> predictions of surface properties. The resulting variants are a vast improvement on the parent antibody's viscosity issues and offer insight into the mechanism of self-association.

mAbsVol. 17(1)
AstraZeneca (Singapore) (SG), AstraZeneca (Brazil) (BR), AstraZeneca (Poland) (PL), AstraZeneca (United States) (US)
AstraZeneca
Good health and well-being
Openalex Percentile: Top 8%
Protein purification and stability
3.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.